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Abstract
Background: High intensity focused ultrasound (HIFU) is an emerging non-invasive treatment modality
for localized treatment of cancers. While current clinical strategies employ HIFU exclusively for thermal
ablation of the target sites, biological responses associated with both thermal and mechanical damage from
focused ultrasound have not been thoroughly investigated. In particular, endogenous danger signals from
HIFU-damaged tumor cells may trigger the activation of dendritic cells. This response may play a critical
role in a HIFU-elicited anti-tumor immune response which can be harnessed for more effective treatment.
Methods: Mice bearing MC-38 colon adenocarcinoma tumors were treated with thermal and mechanical
HIFU exposure settings in order to independently observe HIFU-induced effects on the host's
immunological response. In vivo dendritic cell activity was assessed along with the host's response to
challenge tumor growth.
Results:  Thermal and mechanical HIFU were found to increase CD11c+ cells 3.1-fold and 4-fold,
respectively, as compared to 1.5-fold observed for DC injection alone. In addition, thermal and mechanical
HIFU increased CFSE+ DC accumulation in draining lymph nodes 5-fold and 10-fold, respectively.
Moreover, focused ultrasound treatments not only caused a reduction in the growth of primary tumors,
with tumor volume decreasing by 85% for thermal HIFU and 43% for mechanical HIFU, but they also
provided protection against subcutaneous tumor re-challenge. Further immunological assays confirmed an
enhanced CTL activity and increased tumor-specific IFN-γ-secreting cells in the mice treated by focused
ultrasound, with cytotoxicity induced by mechanical HIFU reaching as high as 27% at a 10:1 effector:target
ratio.
Conclusion:  These studies present initial encouraging results confirming that focused ultrasound
treatment can elicit a systemic anti-tumor immune response, and they suggest that this immunity is closely
related to dendritic cell activation. Because DC activation was more pronounced when tumor cells were
mechanically lysed by focused ultrasound treatment, mechanical HIFU in particular may be employed as a
potential strategy in combination with subsequent thermal ablations for increasing the efficacy of HIFU
cancer treatment by enhancing the host's anti-tumor immunity.
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Background
High-Intensity Focused Ultrasound (HIFU) has recently
emerged as a promising non-invasive treatment modality
for localized solid malignancies [1]. The fundamental
principle of HIFU is to focus an acoustic beam to a small,
well-defined target region. For current clinical treatment,
lesion formation occurs primarily through the accumula-
tion of heat and the subsequent coagulative necrosis at the
focus, with temperatures exceeding 65°C as the target tis-
sue absorbs the focused acoustic energy. With a typical
HIFU system, the size of the induced lesion is approxi-
mately 10 mm × 1 mm. Thus, complete ablation of a
tumor site is performed through progressive scanning of
the tumor volume with the assistance of image guidance,
such as magnetic resonance imaging or B-mode ultra-
sound. This treatment can be performed external to the
body, provided a path devoid of air or other gaseous
regions between the HIFU transducer and the target is
available. In addition to the thermal mechanism, HIFU-
induced tissue damage can also occur through mechanical
means. With longer exposures at high pressures, HIFU can
induce cavitation, the formation of microbubbles under
high tensile pressure, with the resultant secondary shock
wave generation and jet formation upon inertial bubble
collapse [2,3]. This mechanism can cause mechanical lysis
of tumor cells. Because the onset of cavitation in vivo is
unpredictable, this method has been generally avoided in
early clinical applications [2]; however, recent studies sug-
gest that cavitation can be used to enhance HIFU-induced
thermal ablation, as well as in other potential therapeutic
applications such as ultrasound-mediated gene transfer
and drug delivery [4-6].
Compared to conventional cancer therapy modalities,
HIFU has the advantages of being noninvasive and gener-
ally well-tolerated by the patient, enabling it to be admin-
istered repetitively. Despite this advantage, several
limitations in the current form of HIFU cancer therapy
still exist. First, incomplete tissue necrosis, especially in
large tumors, may lead to local recurrence of the tumor
post-treatment. For example, about 20% local recurrence
of soft tissue sarcoma has been reported [7]. This phe-
nomenon presumably occurs due to inhomogeneities in
tissue properties and heat conduction. Second, HIFU can-
not be used to kill metastatic cancer cells outside the pri-
mary tumor site. In fact, distant metastasis, especially in
the air-rich lung tissue, is a major cause of mortality fol-
lowing clinical HIFU therapy [8]. Clearly, the quality and
effectiveness of HIFU cancer therapy need further
improvement.
Historically, research in HIFU has been focused almost
exclusively on enhancing thermal ablation efficiency with
more precise control of targeting and monitoring of lesion
formation, while largely ignoring the diverse range of bio-
logical responses that may be induced by HIFU. One of
the most important biological consequences of HIFU
treatment is the creation of a large amount of tumor anti-
gens in the form of necrotic cells and the local release of a
diverse array of endogenous danger signals from HIFU-
damaged tumor cells. This biological response has the
potential to stimulate an anti-tumor immune response
[9,10]. However, little is known about how such signifi-
cant HIFU-induced changes in the tumor microenviron-
ment may influence the host's anti-tumor immune
response. It is nevertheless interesting to note that several
clinical studies have provided preliminary evidence that
suggest HIFU treatment could affect the patient's immune
status. For example, a marked increase in CD3+ and CD4+
subsets and in the CD4+/CD8+ ratio in peripheral blood of
cancer patients has been observed following HIFU treat-
ment [8,11,12]. In addition, several animal studies have
revealed encouraging evidence that suggests HIFU treat-
ment may induce systemic anti-tumor immunity. For
example, Yang et al. reported that HIFU treatment of sub-
cutaneous murine C1300 neuroblastoma could cause a
significant reduction in subsequent challenged tumor
growth [13]. Despite these previous efforts, the specific
immune response elicited by HIFU has not been deter-
mined using well-established immunologic assays, and
the underlying mechanism is largely unknown. A strong
anti-tumor immune response may help to combat resid-
ual tumor cells at the primary treatment site and to sup-
press distant metastasis. This potential for HIFU-elicited
anti-tumor immunity clearly warrants a thorough investi-
gation for the further development of effective cancer
treatment with focused ultrasound.
Anti-tumor immunity is initiated primarily by dendritic
cells (DC), which capture antigens in peripheral tumor
tissues and migrate to the proximal draining lymph nodes
(DLN). There, the DC present the captured antigens and
sensitize antigen-specific T cells, both CD4+ helper cells
and CD8+ cytotoxic T lymphocytes (CTL), to either
directly attack tumor cells or to express cytokines that trig-
ger other cells to perform this task [14,15]. To initiate an
effective immune response, DC must be stimulated by
"danger signals" to undergo a process of maturation.
Based on Matzinger's danger theory, the maturation of DC
can be induced by endogenous danger signals released
from distressed or injured cells, such as those exposed to
pathogens, toxins, or mechanical damage [15].
One of the biological consequences of HIFU treatment is
the induction of tumor cell necrosis, resulting in the
release of tumor antigens and endogenous danger signals.
Such a microenvironment could attract DC to the treat-
ment site, where they can capture the tumor antigens,
mature, and migrate to adjacent draining lymph nodes to
initiate an anti-tumor immune response. In an earlyJournal of Translational Medicine 2007, 5:34 http://www.translational-medicine.com/content/5/1/34
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proof-of-principle study [16], we demonstrated in vitro
that HIFU treatments cause both thermal and mechanical
necrosis. This effect leads the damaged tumor cells to
release endogenous danger signals (ATP and hsp60),
which could stimulate the maturation of DCs. Based on
this observation, we postulate that the release of endog-
enous danger signals from HIFU-damaged tumor cells
and the consequent activation of DCs may constitute an
important mechanism for HIFU-induced anti-tumor
immunity. Furthermore, we have demonstrated that the
immuno-stimulatory effect of mechanically lysed tumor
cells is much stronger than that of thermally ablated
tumor cells, which are the predominant outcome of cur-
rent HIFU cancer therapy. These findings suggest that
alternative HIFU treatment strategies that promote
mechanical lysis of the tumor cells (in contrast to purely
thermal ablation) may elicit a stronger anti-tumor
immune response.
The objective of this study is therefore three-fold: 1) to
assess HIFU-induced anti-tumor immunity, 2) to investi-
gate the underlying immunologic mechanism, and 3) to
selectively produce either thermal or mechanical damage
in the target tumor tissue in order to independently
observe HIFU-induced effects on the host's immunologi-
cal response. Subsequently, we compared the in vivo DC
maturation and systemic anti-tumor immune response
elicited by these two different HIFU treatment strategies.
In-depth analysis of these systems may enable the devel-
opment of improved focused ultrasound treatment strate-
gies with increased efficacy against recurrence and
metastasis. Our results confirm that HIFU treatment can
indeed elicit a systemic anti-tumor immune response. Fur-
thermore, HIFU-induced anti-tumor immunity is found
to be closely related to DC activation and can be enhanced
by mechanical lysis of the tumor cells.
Methods
Animal Model
C57BL/6 female mice, 5–8 weeks old, were purchased
from the Jackson Laboratory (Bar Harbor, ME) and han-
dled in accordance with the established animal care pol-
icy. All animal studies were approved by the Duke
University Institutional Animal Care & Use Committee.
Tumor Model
MC-38 mouse colon adenocarcinoma tumor cell line was
kindly provided by Dr. Jeffrey Schlom of NCI (Bethesda,
MD). EL4 Mouse lymphoma cell line was purchased from
American Type Culture Collection (ATCC). Both cell lines
were maintained in complete Dulbeco's modified eagle
medium (DMEM), supplemented with 10% heat-inacti-
vated fetal bovine serum (FBS) (Gibco, USA) at 37°C and
5% CO2. A tumor model was prepared by injecting 1 × 106
MC-38 tumor cells suspended in 50 μl of PBS subcutane-
ously in the left hindlimb of the C57BL/6 mice. The tumor
was allowed to grow for 7–9 days to reach a maximum
diameter of 8–10 mm before HIFU treatment.
In Vivo HIFU Exposure System
Figure 1A shows schematically the HIFU exposure system
used in this study. The HIFU transducer (H-102, Sonic
Concepts, Seattle, WA) was mounted at the bottom of a
plexiglass test chamber (40 × 30 × 15 cm) filled with
degassed water (37°C). This transducer has a focal length
of 63 mm and was operated at 3.3 MHz (3rd harmonic),
driven by sinusoidal signals produced by a function gen-
erator (33120A, Agilent, Palo Alto, CA) connected in
series with a 55-dB power amplifier (A150, Electronic
Navigation Industries, Rochester, NY). The operation of
the HIFU system was controlled by LabView programs via
a GPIB board installed in a PC. During the experiment,
the anesthetized tumor-bearing mouse was fixed in a cus-
tom-designed animal holder, which was connected to a 3-
D positioning system driven by computer-controlled step
motors (Velmex, Bloomfield NY). To facilitate alignment
of the tumor to the HIFU focus, a portable ultrasound
imaging system (Terason 2000, Terason, Inc., Burlington,
MA) with a 5/10 MHz probe was used to provide B-mode
images of the tumor cross section. The medial plane of the
tumor was aligned with the focus of the HIFU transducer
using this imaging system. Figure 1B shows an example of
the B-mode ultrasound images of the tumor grown in the
hindlimb of the mouse. As shown in the figure, the tumor
outline was clearly defined, with the focus of the HIFU
transducer highlighted with a cross-hair indicator. The
pressure waveform and distribution in the focal plane of
the HIFU transducer in water were measured and the -6 dB
beam sizes along and transverse to the transducer axis
were determined to be 5 × 0.6 mm [17]. Due to the beam
size of the transducer, treatment of the tumor was accom-
plished through progressive scanning of the whole tumor
volume point-by-point, translating the tumor-bearing
mouse incrementally with the 3-D step motor positioning
system. The tumor was scanned from the lower right cor-
ner 2 mm inside the tumor boundary, progressing from
right to left with a step size of 1.0 mm. Typically, a total of
12 to 16 points were treated depending on the tumor size.
Temperature Measurement
The temperature profile at the HIFU focus was measured
by using a 0.1 mm bare-wire thermocouple (Custom
designed IT-23, Physitemp Inc, Clifton, NJ) inserted into
the tumor tissue. Temperature output voltage was regis-
tered in an electronically compensated isothermal termi-
nal block (TC-2190, National Instrument) and
subsequently conditioned and sampled at a rate of 60 Hz
using a Data Acquisition Board (NI4351, National Instru-
ment) controlled by a LabView program. The thermocou-
ple embedded in the tumor was first aligned to the HIFUJournal of Translational Medicine 2007, 5:34 http://www.translational-medicine.com/content/5/1/34
Page 4 of 11
(page number not for citation purposes)
focus by operating the HIFU transducer at a low intensity
while scanning the tumor across the acoustic field to
search for the position of maximum temperature increase.
Using this approach, temperature elevations inside the
tumor tissue were measured for the designated HIFU
exposure conditions.
Cavitation Detection
Cavitation activities inside the tumor tissue during HIFU
treatment were monitored by B-mode ultrasound imaging
and passive cavitation detection (PCD). The inertial cavi-
tation bubbles inside the tumor tissue could be identified
by hyperechogenicity on the B-mode ultrasound images
[18]. For PCD measurements, a 3.5-MHz focused trans-
ducer (V380, Panametrics Inc, Waltham, MA) was posi-
tioned confocally with the 3.3-MHz HIFU transducer. The
data acquisition and signal processing protocols
employed are similar to previously reported procedures
[19]. Briefly, FFT spectrums of the acoustic emission sig-
nals emanating from HIFU-induced cavitation bubbles
inside the tumor were averaged and compared at different
exposure settings. RMS amplitude of the broadband noise
signals for each FFT spectrum between 4.5 and 5.5 MHz
was further calculated and presented in time sequence.
Immunohistochemistry
Two days after the HIFU treatment, tumors were surgically
excised, freshly frozen in Tissue-Tek O.C.T. compound
(Sakura Finetek, Torrance, CA USA), and sectioned at 6
μm thickness. For immunohistochemistry, the cryostat
sections were fixed in acetone and immunostained with
hamster anti-mouse CD11c mAb (clone HL3, PharMin-
gen). Subsequently, the antibody was visualized using an
anti-hamster Ig HRP detection kit (Pharmingen) follow-
ing the manufacturer's protocol. Finally, sections were
counterstained with hematoxylin and evaluated by light
microscopy.
Generation of Murine DC
Murine DC were generated from the bone marrow of mice
using established protocols [20]. Briefly, marrow from tib-
ias and femurs of C57BL/6 mice were harvested, followed
by treatment of the precursors with ammonium chloride
Tris buffer for 3 min at 37°C to deplete the RBC. The pre-
cursors were plated in RPMI 1640 (Sigma, Sigma-Aldrich,
St. Louis, MO)-10% FCS (GIBCO®, Invitrogen, Carlsbad,
CA) with GM-CSF (10 ng/ml) and IL-4 (10 ng/ml)
(PharMingen, San Diego, CA). Cells were plated at 1 × 106
cells/ml and incubated at 37°C and 5% CO2. Three days
later, the floating cells (mostly granulocytes) were
removed, and the adherent cells were replenished with
fresh medium containing GM-CSF and IL-4. Non-adher-
ent cells were harvested on day 6 as immature DC.
Migration Assay of DC
For DC migration studies [21], day 6 DC were washed and
labeled with 1 μM CFSE (Molecular Probes, Eugene, OR)
following the manufacturer's protocol. CFSE-labeled DC
were injected intratumorally 1 day after HIFU treatment.
Two days after DC injection, the draining lymph nodes
(LN) were harvested and processed, as described by Vre-
mec and Shortman [22]. Briefly, inguinal LN were
removed, and cell suspensions were obtained after diges-
tion with Liberase CI and Dnase I (Roche) for 40 min at
37 °C and treatment with 50 mM EDTA for 5 min to dis-
rupt the T cell-DC complexes. The total LN cells were
counted, washed, and stained with anti-CD11 mAbs (BD
PharMingen, San Diego, CA) for flow cytometry analysis.
After gating on live cells, 106 events were acquired to
quantify the absolute number of migrated DCs per LN
(CFSE-labeled CD11c+ cells).
CTL Assays [23]
Spleens were harvested from euthanized tumor-bearing
mice 10 days after HIFU treatment. Splenocytes (3 × 107)
were re-stimulated for 5 days in vitro with mitomicin C-
pretreated MC-38 cells (3 × 106). Re-stimulated spleno-
cytes were used as effector cells. Cytotoxic activity against
target MC-38 (specific) or EL4 (irrelevant) tumor cells was
assayed at different effector:target ratios by lactate dehy-
drogenase (LDH) release assay according to the manufac-
turer's instructions (Promega). LDH release assays were
chosen due to radioactivity and variability concerns with
chromium release assays. For the CTL assays, three inde-
pendent experiments were performed with six replicate
wells included in each treatment. Cytotoxicity % was cal-
culated as:
experimental culture medium background
maximum LDH release
−







HIFU exposure system and B-mode guidance Figure 1
HIFU exposure system and B-mode guidance. (A) Dia-
gram of the in vivo HIFU exposure setup. (B) Alignment of the 
mouse tumor with the focus of the HIFU transducer was 
aided by B-mode ultrasound imaging.Journal of Translational Medicine 2007, 5:34 http://www.translational-medicine.com/content/5/1/34
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ELISPOT Assay [24]
Splenocytes from mice in each group were restimulated in
vitro by culture with mytomicin-pretreated MC-38 or EL4
tumor cells (20:1 responder-to-stimulator ratios) for 48 h.
Re-stimulated splenocytes (1 × 106  cells in 100 μl
medium) were then plated in 96-well nitrocellulose filter
plates pre-coated with anti-mouse interferon-γ antibody
(anti-IFN-γ Ab). After incubation for 24 h at 37°C and 5%
CO2, the plates were washed with PBS, and "spots," corre-
sponding to cytokine-producing cells, were visualized by
incubation with 100 μl per well of biotinylated anti-
mouse IFN-γ Ab (R&D Systems, Inc) overnight at 4°C.
This was followed by incubation with 100 μl per well of
streptavidin-alkaline phosphatase for 2 h at room temper-
ature and 100 μl per well of BCIP/NBT substrate solution
(ELISpot Blue Color Module, ICI Americas, Inc., Wilming-
ton, DE) in the dark for 30 min at room temperature. IFN-
γ spot-forming cells were counted using a Zeiss Axioplan
II ELISPOT reader system using KS version 4.3 software
(Carl Zeiss, Thornwood, N.Y.). The results were expressed
as the number of spot-forming cells per 106 input cells.
Overall, three independent experiments were performed
with six replicate wells included in each treatment.
Statistical Analysis
Tests of statistical significance were performed using
Statview 4.1 (Abacus Concepts, Berkeley, CA). Results
were acquired from the Student's t test using a two-tailed
distribution. Statistical results are reported as P values.
Results
Temperature Increase, Cavitation, and Tissue Injury
Two different HIFU exposure conditions were employed
to compare the contribution of thermal vs. mechanical
damage to HIFU-induced anti-tumor immunity. For ther-
mal HIFU, the transducer was run in continuous wave
(CW) mode at a comparatively low pressure level (P+ =
19.9 MPa, P- = -7.7 MPa) and a short exposure time (3 s)
to achieve a rapid temperature rise in the tumor tissue
while limiting cavitation-mediated tissue damage. In con-
trast, for mechanical HIFU, the transducer was operated in
burst mode with a duty cycle of 2% with a higher pressure
level (P+ = 34.1 MPa, P- = -12.5 MPa) and a longer expo-
sure time (30 s) to limit temperature increase while gener-
ating strong cavitation, and thus causing mechanical lysis
of the tumor cells.
In thermal HIFU treatment, the temperature in the tumor
tissue at the HIFU focus increased rapidly to greater than
70°C within a three second exposure, as shown in Fig. 2A.
This temperature profile is representative of the clinical
HIFU dosage used in cancer therapy [25,26]. Visual exam-
ination of the tumor tissue after thermal HIFU treatment
revealed regular and well-defined thermal lesions (Fig.
2C). With mechanical HIFU, the focal temperature in the
Characteristics of thermal and mechanical HIFU treatments Figure 2
Characteristics of thermal and mechanical HIFU 
treatments. (A) In vivo temperature profile, (B) representa-
tive frequency spectrum of passive cavitation detection 
(PCD) signals, and (C) images of tumor tissue injury pro-
duced by different HIFU treatmentsJournal of Translational Medicine 2007, 5:34 http://www.translational-medicine.com/content/5/1/34
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tumor tissue increased slowly to less than 55°C within a
30 second exposure (Fig. 2A). However, the development
of bright hyperechoic regions at the HIFU focus in B-
mode ultrasound images indicates cavitation activity (Fig.
3). In addition, Fig. 2B shows that mechanical HIFU expo-
sures produced broader and higher amplitude acoustic
emission signals based on passive cavitation detection.
This strong cavitation activity was further confirmed by
visual examination of the tumor post-treatment, revealing
tumor tissue disruption (Fig. 2C). Altogether, these results
suggest that a significantly higher level of cavitation activ-
ities and associated mechanical lysis was generated in the
targeted tumor tissue by the mechanical HIFU exposure as
compared with conventional thermal HIFU conditions.
DC Infiltration and Migration to DLN
In our previous in vitro study, we have demonstrated that
HIFU treatment can cause the release of endogenous dan-
ger signals from damaged tumor cells and stimulate the
maturation of DCs. Moreover, the immuno-stimulatory
effect of mechanically lysed tumor cells was found to be
much stronger than that of thermally ablated tumor cells
[16]. To confirm this observation in vivo, we first evaluated
DC infiltration into HIFU-treated tumors by immunohis-
tochemistry. Tumor tissue samples were collected 1–2
days after HIFU treatment, and 6-μm cryostat sections
were cut and stained with anti-CD11c Abs. Figure 4 shows
the results of a representative experiment. In the untreated
tumor, only a small amount of DC infiltration was
observed, as indicated by brown regions in the image. In
contrast, DC infiltration was significantly enhanced in
HIFU-treated tumor tissues, especially in regions sur-
rounding the lesions. Furthermore, mechanical HIFU
treatment was found to generate more pronounced DC
infiltrations than thermal HIFU treatment. The DC infil-
tration was most significant one day after HIFU treatment,
and gradually decreased from day 2. Concomitantly, sub-
stantial enlargement of the draining lymph nodes (DLN)
in HIFU-treated mice was observed on day 1, reaching
maximum size between day 3 and day 4 (data not
shown). These observations suggest that HIFU treatment
might attract DC to the damaged regions, and, following
in situ activation by the endogenous danger signals
released from the damaged tumor cells, these infiltrated
DC could migrate to DLN.
To examine this hypothesis, in vivo DC migration was
assessed by monitoring the accumulation of CFSE-labeled
DC in the regional DLN. In vitro-generated immature DCs
were labeled with fluorescent dye CFSE and injected into
the tumor one day following HIFU treatment. Draining
lymph nodes were harvested 2 days after DC injection,
from which single cell suspensions were prepared follow-
ing an established protocol [22]. DLN cells were stained
with anti-CD11c Ab, and the number of LN total cells,
DC, and CD11c+ and CFSE+ cells were measured by FACS
analysis. Consistent with the observation of DLN enlarge-
ment following HIFU treatment, a significant increase in
the total cell number (Fig. 5A) and the total CD11c posi-
tive DC (Fig. 5B) in the DLN were observed. For total cell
count, thermal HIFU treatment resulted in an average 3.4-
fold increase from the control experiment, as opposed to
HIFU-induced DC infiltration Figure 4
HIFU-induced DC infiltration. HIFU-enhanced DC infil-
tration into the tumor. Tumor tissue samples were collected 
1–2 days after HIFU treatment. 6-μm cryostat sections were 
cut and stained with anti-CD11c Abs. Then the antibody was 
visualized using the Anti-Hamster Ig HRP detection kit. The 
sections were counterstained with hematoxylin.
Ultrasound imaging of HIFU-induced cavitation Figure 3
Ultrasound imaging of HIFU-induced cavitation. Time 
progression of a mechanical HIFU-exposure with B-mode 
ultrasound imaging. Bright hyperechoic spots generated by 
HIFU indicate regions of cavitation.Journal of Translational Medicine 2007, 5:34 http://www.translational-medicine.com/content/5/1/34
Page 7 of 11
(page number not for citation purposes)
an average 1.6-fold increase with DC injection alone. Fur-
thermore, mechanical HIFU resulted in an average 4.6-
fold increase over control experiments. For the total
number of CD11c+ DC, thermal HIFU treatment pro-
duced a 3.1-fold increase over the average 1.5-fold
increase observed with DC injection alone. Mechanical
HIFU produced an average 4.0-fold increase. The results
for both thermal and mechanical HIFU exhibit a statisti-
cally significant difference (P < 0.05) over those for DC
injection alone, suggesting that the enlargement of DLN
following HIFU treatment may result directly from the
migration of mature DC to the DLN. This speculation was
further verified by the detection of highly specific CFSE-
labeled DC accumulation in the regional DLN. In con-
trast, no CFSE+ DC were detected in the inguinal DLNs
contra-lateral to the DC-injection site and in the non-
draining axillary LN (data not shown). Quantitatively, as
shown in Fig. 5C and 5D, although a modest accumula-
tion of CFSE+ DC in the DLN of the mice that received DC
injection only (i.e., without HIFU treatment) was
detected, about 5-fold more CFSE+ DCs were detected in
mice treated by the thermal HIFU. In addition, when com-
pared with mice in the control groups, 10-fold more
CFSE+ DCs were detected in mice treated by the mechani-
cal HIFU protocol. Altogether, these results demonstrate
that HIFU treatment can lead to the infiltration of DC into
the target tumor, whereby DC, upon maturation, will
migrate and accumulate in the DLN. Comparing the two
exposure conditions, mechanical HIFU treatment was
found to be more effective in prompting this immuno-
logic response.
HIFU-Induced Systemic Anti-Tumor Response
To further assess whether HIFU treatments could induce a
systemic anti-tumor immune response in vivo, tumor chal-
lenge experiments were performed one day following
either thermal or mechanical HIFU treatment of the pri-
mary tumor by injecting 1 × 106 MC-38 cells subcutane-
ously in the contralateral hindlimb. The results show that
both thermal and mechanical HIFU treatment impaired
primary tumor growth, with thermal treatment providing
more significant, long-term suppression. Figure 6A shows
an average thermal HIFU-treated tumor volume 85%
smaller than those left untreated, while tumors treated
with mechanical HIFU were, on average, 43% smaller
than those from control experiments. However, mechani-
cal HIFU was found to have a stronger retarding effect on
challenge tumor growth (Fig. 6B). To further quantify the
anti-tumor immune response, we examined the CTL
response following different HIFU treatments. As shown
in Fig. 6C, statistically significant increases in CTL activi-
ties were detected following both thermal and mechanical
HIFU treatments. Furthermore, mechanical HIFU was
found to produce a much more profound increase in CTL
activity than thermal HIFU with cytotoxicity reaching as
HIFU-induced DC migration Figure 5
HIFU-induced DC migration. HIFU treatment-induced 
DC migration to DLN and consequent LN congestion. CFSE-
labeled immature bone marrow-derived DCs were injected 
into tumor 1 day after HIFU treatment. The (A) total cell 
number, (B) total number of DC(CD11c+ cells), and (C) 
migrating DC (CFSE+ CD11c+ cells) recovered in DLN on 
day 2 were determined by flow cytometry. Data points rep-
resent the mean ± SD for each group (n = 8). *P < 0.05 ver-
sus DC injection only control group. (D) Representative 
histogram illustrating the population of CFSE+ CD11c+ cells 
within the DLN of mice subjected to different treatments.Journal of Translational Medicine 2007, 5:34 http://www.translational-medicine.com/content/5/1/34
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high as 27% at a 10:1 effector:target ratio. No cytolytic
activity of CTL against irrelevant EL4 cells was observed
(data not shown), indicating that the HIFU-induced CTL
was specific to the MC38 tumor. In subsequent experi-
ments, we further evaluated whether HIFU treatment
could elicit tumor-specific IFN-γ-secreting cells using
ELISPOT assay. Previous studies have demonstrated that
in vitro tumor-specific IFN-γ production by host-derived T
cells correlated with systemic anti-tumor immunity in vivo
[27]. Figure 6D shows that splenocytes retrieved on day
16 after tumor inoculation in HIFU-treated mice con-
tained significantly more tumor-specific IFN-γ-secreting
cells compared with splenocytes from the control group.
This response was immunologically specific to MC38
tumor cells since it could not be detected spontaneously
or in response to the stimulation of irrelevant EL4 cells.
Mice treated with mechanical HIFU exhibited a 3.6-fold
increase in IFN-γ-secreting cells when compared to the
control group, while thermal HIFU yielded a 1.6-fold
increase. These results are consistent with those from
Tumor growth and cytotoxic activity after HIFU treatment Figure 6
Tumor growth and cytotoxic activity after HIFU treatment. HIFU treatments inhibited the growth of (A) primary and 
(B) challenged tumors, and induced tumor-specific CTL response (C), and IFN-γ-secreting cells (D) in the spleens of treated 
mice. C57BL/6 mice were inoculated s.c. on right hind leg with 5 × 105 MC38 tumor cells and treated with different HIFU on 
day 9 of tumor inoculation. Mice were challenged with 1 × 106 MC38 tumor cells by s.c. inoculation on the left hind leg one day 
after HIFU treatment. Both primary and challenged tumor growth were monitored daily. Splenocytes obtained from control 
and treated mice 10 days after HIFU treatment were re-stimulated with mytomicin-pretreated MC-38 or EL4 tumor cells and 
CTL and ELISPOTS assays were performed. Results were expressed as mean value ± SD for each group (n = 8). *P < 0.05; **P 
< 0.001 versus non-treatment control. This experiment is representative of three experiments with consistent results.Journal of Translational Medicine 2007, 5:34 http://www.translational-medicine.com/content/5/1/34
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tumor challenge and CTL evaluation experiments, with
mechanical HIFU affecting the tumor microenvironment
much more profoundly than thermal HIFU. Taken all
together, these results demonstrate that HIFU treatment
can indeed induce an anti-tumor immune response,
which is further enhanced by the mechanical lysis of the
tumor tissues.
Discussion
The present study was carried out to compare the anti-
tumor immune response induced by two distinctly differ-
ent HIFU treatment strategies in vivo. HIFU treatments not
only can produce a reduction in the growth of the primary
tumor but may also suppress distant tumor growth, indi-
cating the induction of a systemic anti-tumor immunity.
HIFU-induced anti-tumor immunity was confirmed by
significantly enhanced specific CTL activity and increased
tumor-specific IFN-γ-secreting cells detected in the HIFU-
treated mice. In concordance with our previous in vitro
results [16], mechanical HIFU was found to consistently
induce a stronger anti-tumor immune response than ther-
mal HIFU in all of these immunological assays.
Although the mechanisms underlying HIFU-induced anti-
tumor immunity may be complex, our findings in this
study suggest that HIFU can stimulate the infiltration of
DCs into damaged tumor tissues. As the most effective
antigen-presenting cells (APCs), DCs are initiators and
modulators of the immune response. Immature DCs are
distributed in peripheral tissues and continuously sample
tissue antigens. In normal healthy tissues, DCs remain in
a "resting state" [14], but when stimulated by an inflam-
matory or "danger" signal, the immature DC undergo a
maturation program. This entails the down-regulation of
antigen uptake capabilities, up-regulation of co-stimula-
tory molecules and chemokine receptors, and migration
to draining LNs, where they liaise with and activate anti-
gen-specific T cells [14]. It has been well established that
the infiltration of DC into the tumor, and the subsequent
migration of DC from the tumor to lymphoid organs, are
critical initial steps during the induction of an anti-tumor
immune response [28-30]. In this study, we have demon-
strated a significantly enhanced DC infiltration into the
tumor followed by pronounced DC migration to the DLN
in HIFU-treated mice. In particular, in comparison to ther-
mal HIFU, mechanical HIFU treatment was found to
induce a more profound DC infiltration and subsequent
migration. This important observation is further sup-
ported by the results of immune response assays showing
that mechanical HIFU can induce greater tumor-specific
CTL activity and an increased amount of IFN-γ-secreting T
cells than thermal HIFU.
The HIFU-induced migration and maturation of DC are
most likely associated with danger signals released from
HIFU-damaged tumor cells. Danger signals were first pos-
tulated by Matzinger in 1994 as part of a model that sug-
gests the immune system responds to danger, rather than
to foreignness [15]. Without danger signals, as in normal
healthy tissues, antigens will be presented to T cells in the
absence of co-stimulation, thus resulting in tolerance.
Danger signals generally consist of molecules that can be
released or produced by cells undergoing stress or abnor-
mal cell death, such as heat-shock proteins [31], nucleo-
tides (ATP, GTP, and mammalian DNA) [32-34], uric acid
[35], and chromatin protein HMBG1 (High Mobility
Group B1) [36]. Some danger signals, such as HMBG1,
also act as chemokines when released from necrotic cells,
recruiting inflammatory cells to the injured site [36,37].
For cancer immunology, the danger signal model argues
that many tumors do not appear dangerous to the
immune system because they initially grow as healthy
cells and do not send out distress signals to activate APCs.
However, the model also predicts that in situ damage to
the tumor cells may "set the stage" for eliciting anti-tumor
immunity by providing sufficient endogenous danger sig-
nals [38]. The results from the present study reinforce this
notion by demonstrating that HIFU-induced in situ tumor
cell damage can lead to the activation of DC and is associ-
ated with a significant anti-tumor immune response. It is
interesting to note that other studies have shown that
chemotherapy or radiotherapy-induced tumor death may
also elicit an effective anti-tumor immune response
[39,40]. In addition, Schueller and colleagues have inves-
tigated immunotherapeutic strategies based on the expres-
sion of HSPs after radiofrequency ablation of tumor tissue
[41].
The interaction of necrosed and dying cells with the
immune system is a complicated process. The various
forms of cell death, such as apoptosis, necrosis,
autophagy, and mitotic catastrophe, are differentiated by
particular combinations of morphological and biochemi-
cal changes, leading to the distinct release patterns of
intracellular contents [42,43]. Physiologic cell death via
apoptosis, in which cells maintain their membrane integ-
rity, has long been considered to be non-immunogenic or
even tolerizing [44]. In contrast, necrotic death is charac-
terized by plasma-membrane disruption and the release
of intracellular content [44]. It is therefore not surprising
that necrosis is usually associated with pathology and can
lead to inflammation and an immune response. However,
it has been shown that both necrotic and apoptotic cells
can be immunostimulatory. Still, there is speculation as to
whether all forms of apoptosis are equivalent [45].
Clearly, a better understanding of the molecular mecha-
nisms concerning different forms of cell death is needed
to maximize the potential utility of endogenous danger
signals. In the setting of HIFU therapy, the major form of
tumor cell death is coagulative necrosis. Wu et al have per-Journal of Translational Medicine 2007, 5:34 http://www.translational-medicine.com/content/5/1/34
Page 10 of 11
(page number not for citation purposes)
formed several clinical studies evaluating the immune
response induced by conventional HIFU thermal abla-
tion, reporting a significant increase in CD4+ lym-
phocytes in the circulation of cancer patients after HIFU
treatment [8,46]. On the other hand, HIFU may also cause
mechanical rupture of the tumor cells through the action
of cavitation bubbles under alternative exposure condi-
tions, as demonstrated in this study. Our previous in vitro
study also demonstrated that, even though many danger
signals could be released from thermal HIFU-damaged
tumor cells to induce DC maturation, their immunostim-
ulatory potential was impaired due to protein denatura-
tion at high temperatures during the rapid coagulative
necrosis. In contrast, cavitation-mediated mechanical
lysis of the tumor cells led to a more complete release of a
diverse array of danger signals, resulting in a stronger acti-
vation of DC [16]. HIFU has definitive immunomodula-
tory properties and is a potential adjuvant for cancer
immunotherapy, if its cell injury potential can be appro-
priately harnessed. The low effectiveness of current immu-
notherapy is most likely due, in large part, to an
unfavorable tumor microenviroment for effective tumor
immunity [47]. For example, tumor cells may actively
produce anti-inflammatory cytokines such as TGF-β, IL-
10 in order to suppress DC function and promote toler-
ance [48]. HIFU treatment, by injuring tumor cells and
providing more effective danger signals, may overcome its
inhibitory effects and turn an unfavorable tumor micro-
enviroment into one that is conducive for DC activation.
Therefore, strategies to enhance tissue necrosis in the
tumor mass with HIFU before intratumoral administra-
tion of DC or cytokines should be evaluated in future
studies.
Conclusion
In the present study, our results show that while mechan-
ical HIFU is not as effective as thermal HIFU in necrosing
tumor tissue, it can induce a stronger anti-tumor response.
While thermal damage produced greater suppression of
tumor growth at the primary site, mechanical damage at
the primary tumor site induced a stronger inhibitory effect
on challenge tumor growth. In addition, mechanical
HIFU caused a more profound infiltration and effective
migration of dendritic cells. Further, mice treated by
mechanical HIFU exhibited enhanced CTL activity and an
increased population of tumor-specific IFN-γ-secreting
cells over control subjects and subjects treated with ther-
mal HIFU.
These preliminary findings demonstrate the feasibility of
developing a synergistic combination of HIFU-induced
thermal ablation for treating the primary tumor mass and
HIFU-elicited host anti-tumor immunity for combating
residual and metastatic tumor cells through mechanical
lysis. Such a strategy may potentially overcome some of
the primary drawbacks associated with current clinical
HIFU therapy and could significantly improve the overall
effectiveness of HIFU in cancer treatment. Future studies
should be carried out to optimize the thermal and
mechanical HIFU exposure settings and to analyze the
tumor microenvironment using such strategies.
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